OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 PRESS RELEASE OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Oxford, United Kingdom – 1 October 2024 –...

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a...

OMass Therapeutics Expands Leadership Team with Two New Appointments PRESS RELEASE OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created rolesPeter Phillips M.D., Ph.D. joins as Senior Vice...

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi...

OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D PRESS RELEASE OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or...